All articles

Sanofi Buys Vigil In $470 Million Deal For Alzheimer’s TREM2 Drug

UroGen Draws A Split Adcom Panel Vote For Bladder Cancer Drug UGN-102

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Prime Medicine Not Keen On PM359 Advancement Despite Initial Data

CRISPR Scores Win For CTX310 Targeting Cholesterol Patients

Vertex Pauses Study Of VX-522 For Patients With Cystic Fibrosis

Biomea Takes Workforce Reduction Play Of 35% For Realignment Plans

Pliant Takes Late-Stage Route After Bexotegrast Issue And Slashes Workforce by 45%

Scroll to Top